Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual)
Windtree Therapeutics (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 13, 2021, at 11:00 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Windtree Therapeutics (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 13, 2021, at 11:00 am ET. The presentation will cover the company's innovative therapies for acute cardiovascular and pulmonary disorders. Windtree is developing istaroxime for acute heart failure and AEROSURF® for respiratory distress in premature infants. A replay will be available on their investor page.
Details
News Market Reaction – WINT
The recorded move for WINT in the trading session of this news was -3.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARRINGTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a company overview and be available for 1x1 meetings at the following upcoming conference:
Ladenburg Thalmann 2021 Virtual Healthcare Conference (Virtual)
Presentation Date: July 13, 2021
Presentation Time: 11:00 am ET
Webcast Link: https://wsw.com/webcast/ladenburg7/wint/2453238
A replay of the presentation will be available on the Investor Page of the company’s website (www.windtreetx.com).
About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee's HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
For more information, please visit the Company's website at www.windtreetx.com.
Contact Information:
Monique Kosse
LifeSci Advisors
212.915.3820 or monique@lifesciadvisors.com
Media contact:
Andrew Mielach
LifeSci Communications
646.876.5868 or amielach@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.